In reaction to disappointing earnings/guidance: MOS -20.0% (also downgraded to Underperform at Merrill), SMSC -13.5%, MAR -10.1%… Select fertilizer/ag names showing weakness following MOS results and analyst downgrades: POT -12.5%, IPI -10.6%, CF -10.3% and TRA -9.5% (all downgraded to Underperform at Merrill); AGU -8.9% (to buy-back 7.9 mln shares through a normal course issuer bid), SYT -8.4%, MON -6.6%… Select metals/mining names showing weakness with lower spot prices and strength in dollar: BHP -5.6%, SLV -5.1%, AU -4.8%, MT -4.5%, RTP -4.4%, GFI -4.0%, HMY -4.0%, AUY -3.6%, NEM -3.3%, GOLD -2.6%, AEM -2.4%, GLD -1.9%… Other news: GE -4.1% (it was reported that stock sale may be offered at $22.25-$22.50, below than $24.50 closing price), WRI -3.8% (announces launch of 2.3 mln common share offering)… Analyst comments: CGV -8.5% (downgraded to Neutral at Merrill), LVS -7.6% (downgraded to Equal Weight at Morgan Stanley), AKAM -7.1% (downgraded to Sell from Neutral at Goldman- DJ), WYNN -4.0% (downgraded to Equal Weight at Morgan Stanley), KLAC -3.2% (downgraded to Underperform at RBC), EBAY -2.9% (downgraded to Equal Weight at Morgan Stanley), AA -2.2% (downgraded to Neutral at Goldman - DJ), HBC -2.0% (downgraded to Market Perform at Keefe Bruyette), JNPR -2.0% (downgraded to Market Perform at Morgan Keegan), HPQ -1.4% (downgraded to Add at Calyon)
In reaction to strong earnings/guidance: BLUD +2.6%, UBS +2.2% (also upgraded to Buy at Deutsche Bank)… Select financial related names showing strength following Senate bill and UBS guidance: NCC +14.9% (declares quarterly dividend of $0.01/share, unchanged from prior dividend), SLM +11.0%, ABK +10.3%, RF +10.1%, AIG +6.8% (prepares large asset sale - FT), SOV +6.0% (upgraded to Market Perform at Friedman Billings), FRE +5.8%, ETFC +4.6%, STT +4.4%, PMI +4.1%, WB +3.4%… Other news: KBR +10.8% (Cramer makes positive comments on MadMoney), CEG +9.5% (EDF looks to trump Buffett’s bid for CEG - FT), RYAAY +8.2% (still checking), STP +1.5% (announces initiatives to expand share of U.S. solar market), BMY +1.5% (U.S. Food & Drug Administration approved the use of REYATAZ boosted with Ritonavir, combination therapy, for previously untreated HIV-1 infected adult patients)… Analyst comments: ASML +2.1% (upgraded to Neutral at Goldman - DJ).
If you found this article interesting please subscribe for updates with any reader or your email. This site is not monetized and 100 percent free. My only form of payment is my readers comments and subscriptions